We really need management to inform us what is going on. There...

We really need management to inform us what is going on. There have been many posts on the fact that the trials of paxalisib are being sponsored by other groups, so Kazia has no control over reporting. That is true, but how can you say you will report something within 8 weeks and still miss this deadline? The paxalisib trials have outcome measures of dfp and os at key time points post enrollment. Once predetermined numbers of patients have passed these time points they can and should report interim data. Patients living longer is fantastic, but doesn't effect reporting once these key patient numbers are passed. Plus evt IS a trial they are sponsoring. It is normal practice to report on outcomes of key dose escalation groups, eg Thesus Phatma's interim data on THE630. The fact we have heard nothing naturally leads investors to assume either recruitment is behind, or they are keeping the data back for some reason. It seems on current performance Dr Friend gets a 'C' for his role in a C suite seat...